News Articles
Jul 08, 2020 San Diego Union-Tribune
San Diego Biotech Snags $137M for Precision Attack on Cancer
Jul 08, 2020 BioWorld
Velosbio Raises $137M Series B for ROR1-targeting Cancer Therapies
Jul 08, 2020 BioCentury
VelosBio Jumps on Megaround Bandwagon with $137M Series B
Jul 08, 2020 MedCity News
VelosBio Raises $137M Series B Round to Support Suite of ROR1-targeting Cancer Drugs
Jul 08, 2020 Endpoints News
Singular Focus on ROR1 Earns VelosBio $137M to Fund PhI ADC and Other Programs
Jul 08, 2020 Wall Street Journal
VelosBio Raises $137 Million Series B Round for Cancer Drug Development
Oct 01, 2018 Wall Street Journal
New Cancer Drugmaker VelosBio Collects $58 Million Series A
Now Leaving The VelosBio Site.
Disclaimer: The information you have requested is not provided by VelosBio Inc. (“VelosBio”) but by a third party and should not be construed as representing the views of VelosBio. VelosBio does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.